{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:49:10Z","timestamp":1793774950246,"version":"4.6.1"},"reference-count":120,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Multiple Myeloma (MM) is a malignant monoclonal gammopathy characterized by the proliferation of plasma cells (PC) in the bone marrow (BM). The tight cross-talk between the BM microenvironment and PC is the hallmark of MM. The BM microenvironment comprises a cellular compartment, consisting of hematopoietic and non-hematopoietic cells. The first includes myeloid cells, T- and B-lymphocytes, natural killer (NK) cells, macrophages, and osteoclasts (OCs). In contrast, non-hematopoietic cell types include BM-derived mesenchymal stromal cells (MSCs), osteoblasts, adipocytes and endothelial cells. Besides the cellular compartment, there is a non-cellular compartment that includes extracellular matrix, growth factors, chemokines, and several cytokines. All these members play distinctive but interacting roles in the progression of MM and the drug response. MM remains an incurable disease, but in the last years immunotherapy has emerged as an important tool in the treatment of MM. The involvement of the BM microenvironment is a relevant barrier in the response to immunotherapy and in generating resistance. In this review, we provide an overview of the BM microenvironment perturbation in MM patients and how it can determine the possible resistance to immunotherapy, including monoclonal antibodies (mAbs), antibody-drug conjugates, chimeric antigen receptor T-cell (CAR-T), and bispecific T-cell engagers (BsAbs).<\/jats:p>","DOI":"10.3389\/fimmu.2025.1613265","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T05:30:22Z","timestamp":1752816622000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Deciphering the bone marrow microenvironment\u2019s role in multiple myeloma immunotherapy resistance"],"prefix":"10.3389","volume":"16","author":[{"given":"Nicolas Thomas","family":"Iannozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Storti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2174\/1568009617666170214102301","article-title":"Multiple myeloma and the immune microenvironment","volume":"17","author":"Kawano","year":"2017","journal-title":"Curr Cancer Drug Targets"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040817","article-title":"NK and NKT cell-mediated immune surveillance against hematological Malignancies","volume":"12","author":"Shimizu","year":"2020","journal-title":"Cancers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0061","article-title":"Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232415448","article-title":"Molecular features of the mesenchymal and osteoblastic cells in multiple myeloma","volume":"23","author":"Iannozzi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040988","article-title":"Challenges for immunotherapy in multiple myeloma: bone marrow microenvironment-mediated immune suppression and immune resistance","volume":"12","author":"Holthof","year":"2020","journal-title":"Cancers"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020217","article-title":"The role of tumor microenvironment in multiple myeloma development and progression","volume":"13","author":"Garcia-Ortiz","year":"2021","journal-title":"Cancers"},{"key":"B7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12943-017-0597-8","article-title":"Mesenchymal stem cells: key players in cancer progression","volume":"16","author":"Ridge","year":"2017","journal-title":"Mol Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10849","article-title":"Microenvironment drug resistance in multiple myeloma: emerging new players","volume":"7","author":"Di Marzo","year":"2016","journal-title":"Oncotarget"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.08.042","article-title":"SDF-1 inhibition targets the bone marrow niche for cancer therapy","volume":"9","author":"Roccaro","year":"2014","journal-title":"Cell Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"107355","DOI":"10.1016\/j.leukres.2023.107355","article-title":"Growth and dormancy control of myeloma cells by mesenchymal stem cells","volume":"133","author":"Mehdi","year":"2023","journal-title":"Leuk Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2016.00107","article-title":"Mitochondria know no boundaries: mechanisms and functions of intercellular mitochondrial transfer","volume":"4","author":"Torralba","year":"2016","journal-title":"Front Cell Dev Biol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"9073","DOI":"10.1038\/srep09073","article-title":"MitoCeption as a new tool to assess the effects of mesenchymal stem\/stromal cell mitochondria on cancer cell metabolism and function","volume":"5","author":"Caicedo","year":"2015","journal-title":"Sci Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0441","article-title":"Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism","volume":"7","author":"Farge","year":"2017","journal-title":"Cancer Discov"},{"key":"B14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.leukres.2017.09.021","article-title":"Maintenance of cellular respiration indicates drug resistance in acute myeloid leukemia","volume":"62","author":"Henkenius","year":"2017","journal-title":"Leuk Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143461","article-title":"Stromal cells serve drug resistance for multiple myeloma via mitochondrial transfer: A study on primary myeloma and stromal cells","volume":"13","author":"Matula","year":"2021","journal-title":"Cancers"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7969","article-title":"Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)","volume":"7","author":"Giallongo","year":"2016","journal-title":"Oncotarget"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2016.04.002","article-title":"Myeloid-derived suppressor cells: The green light for myeloma immune escape","volume":"30","author":"Malek","year":"2016","journal-title":"Blood Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.imlet.2018.04.007","article-title":"The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38","volume":"205","author":"Bolzoni","year":"2019","journal-title":"Immunol Lett"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16881","article-title":"Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma","volume":"191","author":"Kuwahara-Ota","year":"2020","journal-title":"Br J Haematol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"183602","DOI":"10.1155\/2013\/183602","article-title":"Multiple myeloma macrophages: pivotal players in the tumor microenvironment","volume":"2013","author":"Berardi","year":"2013","journal-title":"J Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30070455","article-title":"Tumor-associated macrophages in multiple myeloma: key role in disease biology and potential therapeutic implications","volume":"30","author":"Cencini","year":"2023","journal-title":"Curr Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003975","article-title":"Tumor-associated macrophages in multiple myeloma: advances in biology and therapy","volume":"10","author":"Sun","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09154.x","article-title":"Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells","volume":"158","author":"Kim","year":"2012","journal-title":"Br J Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/path.4860","article-title":"Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation","volume":"241","author":"De Beule","year":"2017","journal-title":"J Pathol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.08.012","article-title":"Interleukin-6 leads to interleukin-10 production in several human multiple myeloma cell lines. Does interleukin-10 enhance the proliferation of these cells","volume":"34","author":"Kovacs","year":"2010","journal-title":"Leuk Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-015-9921-z","article-title":"Interleukin-10 induces both plasma cell proliferation and angiogenesis in multiple myeloma","volume":"21","author":"Alexandrakis","year":"2015","journal-title":"Pathol Oncol Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.356","article-title":"TAMeless traitors: macrophages in cancer progression and metastasis","volume":"117","author":"Aras","year":"2017","journal-title":"Br J Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01947","article-title":"Re-educating\u201d Tumor associated macrophages as a novel immunotherapy strategy for neuroblastoma","volume":"11","author":"Liu","year":"2020","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2207","article-title":"Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4\/CXCL12 axis and promote their polarization toward the M2 phenotype","volume":"5","author":"Beider","year":"2014","journal-title":"Oncotarget"},{"key":"B32","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.immuni.2018.01.006","article-title":"Interleukin-10 directly inhibits CD8(+) T cell function by enhancing N-glycan branching to decrease antigen sensitivity","volume":"48","author":"Smith","year":"2018","journal-title":"Immunity"},{"key":"B34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.canlet.2019.01.012","article-title":"Multiple myeloma cell-derived IL-32gamma increases the immunosuppressive function of macrophages by promoting indoleamine 2,3-dioxygenase (IDO) expression","volume":"446","author":"Yan","year":"2019","journal-title":"Cancer Lett"},{"key":"B35","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.cell.2020.01.022","article-title":"Tissue determinants of human NK cell development, function, and residence","volume":"180","author":"Dogra","year":"2020","journal-title":"Cell"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00293","article-title":"Role of distinct natural killer cell subsets in anticancer response","volume":"8","author":"Stabile","year":"2017","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12176","article-title":"Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA: Dual role in cancer immunosurveillance","volume":"11","author":"Vulpis","year":"2022","journal-title":"J Extracell Vesicles"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007905","article-title":"NK cells CD56bright and CD56dim subset cytokine loss and exhaustion is associated with impaired survival in myeloma","volume":"6","author":"Seymour","year":"2022","journal-title":"Blood Adv"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064835","article-title":"Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells","volume":"8","author":"Sarkar","year":"2013","journal-title":"PLoS One"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006805","article-title":"Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses","volume":"6","author":"Daly","year":"2022","journal-title":"Blood Adv"},{"key":"B42","doi-asserted-by":"publisher","first-page":"100968","DOI":"10.1016\/j.mam.2021.100968","article-title":"NK cell surveillance of hematological Malignancies. Therapeutic implications and regulation by chemokine receptors","volume":"80","author":"Tomaipitinca","year":"2021","journal-title":"Mol Aspects Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/art.39295","article-title":"Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome","volume":"67","author":"Cifaldi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2025.100668","article-title":"Mechanistic insights into bone destruction in multiple myeloma: Cellular and molecular perspectives","volume":"51","author":"Lungu","year":"2025","journal-title":"J Bone Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20110994","article-title":"Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow","volume":"209","author":"Mansour","year":"2012","journal-title":"J Exp Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"8983","DOI":"10.1038\/ncomms9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche","volume":"6","author":"Lawson","year":"2015","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01822","article-title":"Osteoclast immunosuppressive effects in multiple myeloma: role of programmed cell death ligand 1","volume":"9","author":"Tai","year":"2018","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707547","article-title":"Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication","volume":"128","author":"An","year":"2016","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1597","article-title":"The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"m3176","DOI":"10.1136\/bmj.m3176","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Shah","year":"2020","journal-title":"BMJ"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6619","article-title":"Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma","volume":"12","author":"Bisht","year":"2023","journal-title":"Cancer Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121522","article-title":"Therapeutic opportunities with pharmacological inhibition of CD38 with isatuximab","volume":"8","author":"Martin","year":"2019","journal-title":"Cells"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.268656","article-title":"Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma","volume":"106","author":"Kinder","year":"2021","journal-title":"Haematologica"},{"key":"B55","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/leu.2015.240","article-title":"SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide","volume":"30","author":"Jiang","year":"2016","journal-title":"Leukemia"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01771","article-title":"Isatuximab acts through fc-dependent, independent, and direct pathways to kill multiple myeloma cells","volume":"11","author":"Zhu","year":"2020","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04978-6","article-title":"Adverse outcome associated with daratumumab-based treatments in relapsed\/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience","volume":"101","author":"Barbieri","year":"2022","journal-title":"Ann Hematol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280660","article-title":"Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed\/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA","volume":"107","author":"Martin","year":"2022","journal-title":"Haematologica"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/cells9010167","article-title":"Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma","volume":"9","author":"Saltarella","year":"2020","journal-title":"Cells"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004332","article-title":"The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications","volume":"136","author":"Ogiya","year":"2020","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.68148","article-title":"Regulation of CD38 on multiple myeloma and NK cells by monoclonal antibodies","volume":"18","author":"Wu","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9041195","article-title":"Resistance mechanisms towards CD38-directed antibody therapy in multiple myeloma","volume":"9","author":"Franssen","year":"2020","journal-title":"J Clin Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12532","article-title":"Mechanisms of action and clinical development of elotuzumab","volume":"11","author":"Ritchie","year":"2018","journal-title":"Clin Transl Sci"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3117","article-title":"Fratricide of NK cells in daratumumab therapy for multiple myeloma overcome by ex vivo-expanded autologous NK cells","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.139667","article-title":"Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance","volume":"101","author":"de Haart","year":"2016","journal-title":"Haematologica"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020305","article-title":"Targeting CD47 as a novel immunotherapy for multiple myeloma","volume":"12","author":"Sun","year":"2020","journal-title":"Cancers"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1386361","article-title":"CD20-selective inhibition of CD47-SIRPalpha \u201cdon\u2019t eat me\u201d signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab","volume":"7","author":"van Bommel","year":"2018","journal-title":"Oncoimmunology"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0773","article-title":"CD38-driven mitochondrial trafficking promotes bioenergetic plasticity in multiple myeloma","volume":"79","author":"Marlein","year":"2019","journal-title":"Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082240","article-title":"Targeting BCMA in multiple myeloma: advances in antibody-drug conjugate therapy","volume":"15","author":"Xing","year":"2023","journal-title":"Cancers"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.991092","article-title":"Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma","volume":"13","author":"Chekol Abebe","year":"2022","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-20-0227","article-title":"Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma","volume":"2","author":"van de Donk","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137650","article-title":"Cite-seq profiling of T cells in multiple myeloma patients undergoing BCMA targeting CAR-T or bites immunotherapy","volume":"136","author":"Leblay","year":"2020","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2188","article-title":"Bone marrow mesenchymal stromal cells can render multiple myeloma cells resistant to cytotoxic machinery of CAR T cells through inhibition of apoptosis","volume":"27","author":"Holthof","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40164-023-00402-5","article-title":"Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed\/refractory multiple myeloma through single-cell sequencing","volume":"12","author":"Li","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1002\/cm.20175","article-title":"Tumor-derived factors impaired motility and immune functions of dendritic cells through derangement of biophysical characteristics and reorganization of cytoskeleton","volume":"64","author":"Zeng","year":"2007","journal-title":"Cell Motil Cytoskeleton"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012811","article-title":"Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma","volume":"139","author":"Sakemura","year":"2022","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40164-025-00643-6","article-title":"Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meeting","volume":"14","author":"Hu","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.832645","article-title":"Armored BCMA CAR T cells eliminate multiple myeloma and are resistant to the suppressive effects of TGF-beta","volume":"13","author":"Alabanza","year":"2022","journal-title":"Front Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10194593","article-title":"Current state of the art and prospects of T cell-redirecting bispecific antibodies in multiple myeloma","volume":"10","author":"Hosny","year":"2021","journal-title":"J Clin Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012354","article-title":"Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications","volume":"8","author":"Letouze","year":"2024","journal-title":"Blood Adv"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004418","article-title":"Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM","volume":"5","author":"Truger","year":"2021","journal-title":"Blood Adv"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"B98","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3333","article-title":"T-cell characteristics impact response and resistance to T-cell-redirecting bispecific antibodies in multiple myeloma","volume":"30","author":"Verkleij","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00636","article-title":"Deregulation of adaptive T cell immunity in multiple myeloma: insights into mechanisms and therapeutic opportunities","volume":"10","author":"Leblay","year":"2020","journal-title":"Front Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000575","article-title":"Understanding the mechanisms of resistance to T cell-based immunotherapies to develop more favorable strategies in multiple myeloma","volume":"5","author":"Ahn","year":"2021","journal-title":"Hemasphere"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3676","article-title":"Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance","volume":"19","author":"de Haart","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.08.019","article-title":"Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target","volume":"16","author":"Chauhan","year":"2009","journal-title":"Cancer Cell"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1203373","article-title":"Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow","volume":"190","author":"Ramachandran","year":"2013","journal-title":"J Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"Gorgun","year":"2013","journal-title":"Blood"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.11","article-title":"Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells","volume":"29","author":"Ray","year":"2015","journal-title":"Leukemia"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1519300","article-title":"Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects","volume":"16","author":"Horenstein","year":"2025","journal-title":"Front Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16548","article-title":"CD14(+) CD16(+) monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy","volume":"190","author":"Storti","year":"2020","journal-title":"Br J Haematol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.123","article-title":"Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab","volume":"29","author":"Nijhof","year":"2015","journal-title":"Leukemia"},{"key":"B110","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.celrep.2019.04.091","article-title":"Blocking antibodies targeting the CD39\/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies","volume":"27","author":"Perrot","year":"2019","journal-title":"Cell Rep"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01983-0","article-title":"EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma","volume":"37","author":"Chemlal","year":"2023","journal-title":"Leukemia"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/s41467-024-45561-z","article-title":"Epigenetic regulation of CD38\/CD48 by KDM6A mediates NK cell response in multiple myeloma","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2019.04.008","article-title":"Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells","volume":"81","author":"Chen","year":"2019","journal-title":"Leuk Res"},{"key":"B115","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T cell therapy in Multiple Myeloma: current status and future challenges","volume":"14","author":"Swan","year":"2024","journal-title":"Blood Cancer J"},{"key":"B116","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1182\/blood-2023-186395","article-title":"Multimodal single-cell transcriptomic and proteomic correlatives of patients outcomes following anti-BCMA cellular therapy with ciltacabtagene autoleucel (Cilta-cel) in relapsed multiple myeloma","volume":"142","author":"Vieira dos Santos","year":"2023","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0361","article-title":"Immunomodulatory drug costimulates T cells via the B7-CD28 pathway","volume":"103","author":"LeBlanc","year":"2004","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24944","article-title":"Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation","volume":"9","author":"Fostier","year":"2018","journal-title":"Oncotarget"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"B120","doi-asserted-by":"publisher","first-page":"8008","DOI":"10.1200\/JCO.2023.41.16_suppl.8008","article-title":"Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies","volume":"41","author":"Nooka","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1613265\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T05:30:24Z","timestamp":1752816624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1613265\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":120,"alternative-id":["10.3389\/fimmu.2025.1613265"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1613265","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"article-number":"1613265"}}